Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 9084–9086.

https://doi.org/10.1182/blood-2022-158626

Published: 2022

Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 9070–9073.

https://doi.org/10.1182/blood-2022-166715

Published: 2022

Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem

Blood (2022) 140 (Supplement 1): 5291–5292.

https://doi.org/10.1182/blood-2022-162622

Published: 2022

Journal Articles

Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies

Jennie Vagher, Bryan D. Huber, Luke Maese, Archana M Agarwal, Afaf Osman, Ami B. Patel, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Julie D. Asch, Charles J. Parker, Srinivas K. Tantravahi

Blood (2022) 140 (Supplement 1): 11468–11470.

https://doi.org/10.1182/blood-2022-170000

Published: 2022

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

https://doi.org/10.1182/blood-2022-167316

Published: 2022

Journal Articles

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Julia Lee, Charlotte B Wagner, Stacy Prelewicz, Heena P Kurish, Rob Walchack, Danielle Cenin, Seema Patel, Mimi Lo, Danielle Schlafer, Belinda KT Li, R Donald Harvey, Bestis Wasef, Jian Ying, Tibor Kovacsovics

Blood (2022) 140 (Supplement 1): 3242–3243.

https://doi.org/10.1182/blood-2022-170123

Published: 2022

Journal Articles

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan-You Wang, Sarah S. Murray, Jennie Vagher, Tibor Kovacsovics, Jay L. Patel

Blood (2022) 140 (7): 716–755.

https://doi.org/10.1182/blood.2021015135

Published: 2022

Includes: Supplemental data

Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 875.

https://doi.org/10.1182/blood-2021-149115

Published: 2021

Journal Articles

Disease Characteristics of AML Patients with Germline DDX41 Variants

Jennie Vagher, Shobi Venkatachalam, Peng Li, Julie D. Asch, Bryan D. Huber, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Luke Maese, Charles J. Parker, Srinivas K. Tantravahi

Blood (2021) 138 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2021-154117

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2021-151234

Published: 2021

Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2021-145903

Published: 2021

Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-134850

Published: 2020

Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-143265

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 177.

https://doi.org/10.1182/blood-2019-124050

Published: 2019

Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 2145.

https://doi.org/10.1182/blood-2019-131253

Published: 2019

Journal Articles

Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2

Blood (2018) 132 (Supplement 1): 4053.

https://doi.org/10.1182/blood-2018-99-116199

Published: 2018

Journal Articles

Healthcare Utilization and Imputed Costs of Acute Myeloid Leukemia Patients By FLT3 Status and Early Midostaurin Use at a Comprehensive Cancer Center

Minkyoung Yoo, Jyothi Menon, PhD, Connor Willis, PharmD, Sudhir Unni, PhD, Trang Au, PharmD, Joseph Biskupiak, PhD, Briana Ndife, MPH, George J Joseph, BPharm, MS, PhD, Gaetano J Bonifacio, MD, Eytan M. Stein, MD, Srinivas K. Tantravahi, MBBS, Paul J. Shami, MD, Tibor Kovacsovics, MD, Diana Brixner, PhD, David Dean Stenehjem, PharmD

Blood (2018) 132 (Supplement 1): 5857.

https://doi.org/10.1182/blood-2018-99-113479

Published: 2018

NARROW

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Disease Characteristics of AML Patients with Germline DDX41 Variants

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2

Healthcare Utilization and Imputed Costs of Acute Myeloid Leukemia Patients By FLT3 Status and Early Midostaurin Use at a Comprehensive Cancer Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only